{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:54:43Z","timestamp":1767592483886,"version":"3.48.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,4]]},"DOI":"10.7759\/cureus.100779","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:53:33Z","timestamp":1767592413000},"source":"Crossref","is-referenced-by-count":0,"title":["Expert Opinion on the First-Line Management of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in India: The Role of Faricimab"],"prefix":"10.7759","author":[{"given":"Chaitra","family":"Jayadev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna","family":"Bhende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishali","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debdulal","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyen","family":"Deka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Manayath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. World report on vision. (2019). Accessed: June 2, 2025: https:\/\/www.who.int\/publications\/i\/item\/world-report-on-vision."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijceo.2021.102","article-title":"Trends and practices in the management of neovascular age-related macular degeneration (nAMD) amongst ophthalmologists across India: findings of a cross-sectional survey","volume":"7","author":"Bhavsar M","year":"2021","unstructured":"Bhavsar M, Maksane N, Shah U, Madhavan A, Dhar P, Thaker M. Trends and practices in the management of neovascular age-related macular degeneration (nAMD) amongst ophthalmologists across India: findings of a cross-sectional survey. Indian J Clin Exp Ophthalmol. 2021, 7:515-22. 10.18231\/j.ijceo.2021.102","journal-title":"Indian J Clin Exp Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.14","article-title":"The prevalence and risk factors for age-related macular degeneration in rural-urban India, Sankara Nethralaya rural-urban age-related macular degeneration study, report no. 1","volume":"30","author":"Raman R","year":"2016","unstructured":"Raman R, Pal SS, Ganesan S, Gella L, Vaitheeswaran K, Sharma T. The prevalence and risk factors for age-related macular degeneration in rural-urban India, Sankara Nethralaya rural-urban age-related macular degeneration study, report no. 1. Eye (Lond). 2016, 30:688-97. 10.1038\/eye.2016.14","journal-title":"Eye (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4114","article-title":"Prevalence of early and late age-related macular degeneration in India: the INDEYE study","volume":"51","author":"Krishnan T","year":"2010","unstructured":"Krishnan T, Ravindran RD, Murthy GV, et al.. Prevalence of early and late age-related macular degeneration in India: the INDEYE study. Invest Ophthalmol Vis Sci. 2010, 51:701-7. 10.1167\/iovs.09-4114","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.99870","article-title":"Prevalence and determinants of age-related macular degeneration in the 50 years and older population: a hospital based study in Maharashtra, India","volume":"61","author":"Kulkarni SR","year":"2013","unstructured":"Kulkarni SR, Aghashe SR, Khandekar RB, Deshpande MD. Prevalence and determinants of age-related macular degeneration in the 50 years and older population: a hospital based study in Maharashtra, India. Indian J Ophthalmol. 2013, 61:196-201. 10.4103\/0301-4738.99870","journal-title":"Indian J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.APO.0000656992.00746.48","article-title":"Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment","volume":"9","author":"Chaikitmongkol V","year":"2020","unstructured":"Chaikitmongkol V, Cheung CM, Koizumi H, Govindahar V, Chhablani J, Lai TY. Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment. Asia Pac J Ophthalmol (Phila). 2020, 9:260-8. 10.1097\/01.APO.0000656992.00746.48","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051413","article-title":"Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration","volume":"15","author":"Ferro Desideri L","year":"2023","unstructured":"Ferro Desideri L, Traverso CE, Nicol\u00f2 M, Munk MR. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics. 2023, 15:1413. 10.3390\/pharmaceutics15051413","journal-title":"Pharmaceutics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00401-4","article-title":"Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients","volume":"8","author":"Mishra SK","year":"2022","unstructured":"Mishra SK, Kumar P, Khullar S, et al.. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients. Int J Retina Vitreous. 2022, 8:51. 10.1186\/s40942-022-00401-4","journal-title":"Int J Retina Vitreous"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as potential targets in management of retinal disease","volume":"15","author":"Khanani AM","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol. 2021, 15:3747-55. 10.2147\/OPTH.S231801","journal-title":"Clin Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2021.1907846","article-title":"Optical coherence tomography-based prevalence of diabetic macular edema and its associated risk factors in urban South India: a population-based study","volume":"29","author":"Pradhana D","year":"2022","unstructured":"Pradhana D, Swathi Priya MN, Surya J, Bhende M, Laxmi G, Sharma T, Raman R. Optical coherence tomography-based prevalence of diabetic macular edema and its associated risk factors in urban South India: a population-based study. Ophthalmic Epidemiol. 2022, 29:149-55. 10.1080\/09286586.2021.1907846","journal-title":"Ophthalmic Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana RM","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, et al.. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023, 11:474-89. 10.1016\/S2213-8587(23)00119-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_2614_20","article-title":"Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India","volume":"69","author":"Kulkarni S","year":"2021","unstructured":"Kulkarni S, Ramachandran R, Sivaprasad S, et al.. Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. Indian J Ophthalmol. 2021, 69:671-6. 10.4103\/ijo.IJO_2614_20","journal-title":"Indian J Ophthalmol"},{"key":"ref13","unstructured":"Mowatt G, Hern\u00e1ndez R, Castillo M. Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. (2014). Accessed: December 5, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK263934\/."},{"key":"ref14","unstructured":"Roche. Roche\u2019s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness. (2024). Accessed: December 10, 2025: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-12-13b."},{"key":"ref15","unstructured":"CDSCO. Recommendations of the SEC (ophthalmology) made in its 63rd meeting held on February 22, 2023: at CDSCO (HQ), New Delhi. (2023). Accessed: December 5, 2025: https:\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadCommitteeFiles\/Recommendations%20Ophthalmology%2022....."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S502033","article-title":"Clinical evaluation of faricimab in real-world diabetic macular edema in India- a multicenter observational study","volume":"19","author":"Chakraborty D","year":"2025","unstructured":"Chakraborty D, Das S, Maiti A, et al.. Clinical evaluation of faricimab in real-world diabetic macular edema in India- a multicenter observational study. Clin Ophthalmol. 2025, 19:269-77. 10.2147\/OPTH.S502033","journal-title":"Clin Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini H","year":"2024","unstructured":"Agostini H, Abreu F, Baumal CR, et al.. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol. 2024, 262:3437-51. 10.1007\/s00417-024-06531-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni J","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al.. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019, 126:1155-70. 10.1016\/j.ophtha.2019.03.023","journal-title":"Ophthalmology"},{"key":"ref19","article-title":"Evaluation of the effects of VEGF\/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model","volume":"59","author":"Foxton RH","year":"2018","unstructured":"Foxton RH, Uhles S, Gruener S, et al.. Evaluation of the effects of VEGF\/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model. Invest Ophthalmol Vis Sci. 2018, 59:237.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica J","year":"2023","unstructured":"Canonica J, Foxton R, Garrido MG, et al.. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion. Front Cell Neurosci. 2023, 17:1192464. 10.3389\/fncel.2023.1192464","journal-title":"Front Cell Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula JT","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et al.. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016, 8:1265-88. 10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies","volume":"17","author":"Panos GD","year":"2023","unstructured":"Panos GD, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku WM. Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies. Drug Des Devel Ther. 2023, 17:2861-73. 10.2147\/DDDT.S427416","journal-title":"Drug Des Devel Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni J","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, et al.. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020, 138:955-63. 10.1001\/jamaophthalmol.2020.2685","journal-title":"JAMA Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707895","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye\u00a0diseases","volume":"9","author":"Regula JT","year":"2017","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, et al.. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye\u00a0diseases. EMBO Mol Med. 2017, 9:985. 10.15252\/emmm.201707895","journal-title":"EMBO Mol Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski S","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022, 23:9424. 10.3390\/ijms23169424","journal-title":"Int J Mol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong TY","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al.. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024, 131:708-23. 10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff CC","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al.. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet Lond Engl. 2022, 399:741-55. 10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet Lond Engl"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary V","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, et al.. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025, 263:1239-47. 10.1007\/s00417-024-06695-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani AM","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al.. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024, 131:914-26. 10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.11.023","article-title":"Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration","volume":"132","author":"Cheung CM","year":"2025","unstructured":"Cheung CM, Lim JI, Priglinger S, et al.. Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration. Ophthalmology. 2025, 132:519-26. 10.1016\/j.ophtha.2024.11.023","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/biom14030252","article-title":"Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization","volume":"14","author":"Fu Y","year":"2024","unstructured":"Fu Y, Zhang Z, Webster KA, Paulus YM. Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization. Biomolecules. 2024, 14:252. 10.3390\/biom14030252","journal-title":"Biomolecules"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian LM","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KY, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023, 21:133. 10.1186\/s12967-023-03937-7","journal-title":"J Transl Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan CS","year":"2022","unstructured":"Tan CS, Ngo WK, Chay IW, Ting DS, Sadda SR. Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options. Clin Ophthalmol. 2022, 16:917-33. 10.2147\/OPTH.S231913","journal-title":"Clin Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.2-a.s3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff CC","year":"2018","unstructured":"Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Care Spec Pharm. 2018, 24:S3-S15. 10.18553\/jmcp.2018.24.2-a.s3","journal-title":"J Manag Care Spec Pharm"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10442","article-title":"Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor","volume":"199","author":"Oshima Y","year":"2004","unstructured":"Oshima Y, Deering T, Oshima S, et al.. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004, 199:412-7. 10.1002\/jcp.10442","journal-title":"J Cell Physiol"},{"key":"ref36","unstructured":"Csaky KG. Dual inhibition of Ang-2 and VEGF-A with faricimab: advances in understanding and treatment of retinal diseases. (2021). Accessed: December 5, 2025: https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/ophthalmology\/angiogenesis-2021\/Angiogenesis-2021-presenta...."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241613004","article-title":"Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment","volume":"24","author":"Moon BH","year":"2023","unstructured":"Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023, 24:13004. 10.3390\/ijms241613004","journal-title":"Int J Mol Sci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani AM","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, et al.. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023, 37:3574-81. 10.1038\/s41433-023-02553-5","journal-title":"Eye (Lond)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2 M","year":"2021","unstructured":"Nicol\u00f2 M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021, 30:193-200. 10.1080\/13543784.2021.1879791","journal-title":"Expert Opin Investig Drugs"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada M","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al.. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021, 128:234-47. 10.1016\/j.ophtha.2020.07.060","journal-title":"Ophthalmology"},{"key":"ref41","unstructured":"Medically. Four-year outcomes of faricimab in DME: first time safety and efficacy results from the RHONE-X long-term extension trial. (2024). Accessed: December 5, 2025: https:\/\/medically.gene.com\/global\/en\/unrestricted\/ophthalmology\/ASRS-2024\/asrs-2024-presentation-khanani-four-year-ou...."},{"key":"ref42","article-title":"Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b\/4 SALWEEN trial","volume":"66","author":"Lee J","year":"2025","unstructured":"Lee J, Cheung G, Chen S-J, et al.. Faricimab for polypoidal choroidal vasculopathy: week 16 results from the phase 3b\/4 SALWEEN trial. Invest Ophthalmol Vis Sci. 2025, 66:1859-59.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada RC, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S463624","article-title":"Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema","volume":"18","author":"Quah NQ","year":"2024","unstructured":"Quah NQ, Javed KM, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024, 18:1479-90. 10.2147\/OPTH.S463624","journal-title":"Clin Ophthalmol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40100","article-title":"Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration","volume":"15","author":"Cheng AM","year":"2023","unstructured":"Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV. Faricimab effectively resolves intraretinal fluid and preserves vision in refractory, recalcitrant, and nonresponsive neovascular age-related macular degeneration. Cureus. 2023, 15:e40100. 10.7759\/cureus.40100","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"103","author":"Arnold-Vangsted A","year":"2025","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, et al.. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol. 2025, 103:247-56. 10.1111\/aos.16797","journal-title":"Acta Ophthalmol"},{"key":"ref47","article-title":"The real-world efficacy and safety of faricimab in diabetic macular edema: the TAHOE study","volume":"65","author":"Khan H","year":"2024","unstructured":"Khan H, Khan H, Aziz AA, et al.. The real-world efficacy and safety of faricimab in diabetic macular edema: the TAHOE study. Invest Ophthalmol Vis Sci. 2024, 65:6259.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59632-0","article-title":"Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration","volume":"14","author":"Eckardt F","year":"2024","unstructured":"Eckardt F, Lorger A, Hafner M, et al.. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration. Sci Rep. 2024, 14:9600. 10.1038\/s41598-024-59632-0","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036370","article-title":"Comparative efficacy and safety of faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li G","year":"2023","unstructured":"Li G, Zhu N, Ji A. Comparative efficacy and safety of faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2023, 102:e36370. 10.1097\/MD.0000000000036370","journal-title":"Medicine (Baltimore)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis","volume":"40","author":"Watkins C","year":"2023","unstructured":"Watkins C, Paulo T, B\u00fchrer C, Holekamp NM, Bagijn M. Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther. 2023, 40:5204-21. 10.1007\/s12325-023-02675-y","journal-title":"Adv Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004394","article-title":"Intraocular inflammation associated with faricimab therapy: one-year real-world outcomes","volume":"45","author":"Montesel A","year":"2025","unstructured":"Montesel A, Sen S, Preston E, et al.. Intraocular inflammation associated with faricimab therapy: one-year real-world outcomes. Retina. 2025, 45:827-32. 10.1097\/IAE.0000000000004394","journal-title":"Retina"},{"key":"ref52","article-title":"Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database","volume":"65","author":"Patel S","year":"2024","unstructured":"Patel S, Chi G, Patel V, et al.. Retinal vasculitis with or without retinal vascular occlusion among eyes with nAMD or DME treated with IVT agents as recorded in the Vestrum database. Invest Ophthalmol Vis Sci. 2024, 65:5672.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2024.100074","article-title":"Early real-world experience with intravitreal faricimab for neovascular AMD: FAN study","volume":"1","author":"Weber C","year":"2024","unstructured":"Weber C, Schipper P, Stasik I, et al.. Early real-world experience with intravitreal faricimab for neovascular AMD: FAN study. AJO Int. 2024, 1:100074. 10.1016\/j.ajoint.2024.100074","journal-title":"AJO Int"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00379-z","article-title":"Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab","volume":"8","author":"Hayashi-Mercado R","year":"2022","unstructured":"Hayashi-Mercado R, P\u00e9rez-Monta\u00f1o C, Reyes-S\u00e1nchez J, Ram\u00edrez-Estudillo A. Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab. Int J Retina Vitreous. 2022, 8:29. 10.1186\/s40942-022-00379-z","journal-title":"Int J Retina Vitreous"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo ZL","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al.. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021, 128:1580-91. 10.1016\/j.ophtha.2021.04.027","journal-title":"Ophthalmology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong WL","year":"2014","unstructured":"Wong WL, Su X, Li X, et al.. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014, 2:106-16. 10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu M","year":"2022","unstructured":"Xu M, Fan R, Fan X, Shao Y, Li X. Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis. Drug Des Devel Ther. 2022, 16:3241-62. 10.2147\/DDDT.S383101","journal-title":"Drug Des Devel Ther"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0895-z","article-title":"Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade","volume":"34","author":"Adamis AP","year":"2020","unstructured":"Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. Eye (Lond). 2020, 34:1966-72. 10.1038\/s41433-020-0895-z","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431745-expert-opinion-on-the-first-line-management-of-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema-in-india-the-role-of-faricimab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:53:37Z","timestamp":1767592417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431745-expert-opinion-on-the-first-line-management-of-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema-in-india-the-role-of-faricimab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.100779","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}